Tirzepatide and muscle loss: what we know

Tirzepatide weight loss is not made up of fat alone. In the SURMOUNT 1 DXA substudy, participants taking tirzepatide lost fat mass and lean mass over 72 weeks. About 75% of the weight lost was fat mass and 25% was lean mass. That is useful context for anyone worried about preserving muscle or the shape of a particular body area, but it cannot predict what will happen to one person's glutes.^[1] Tirzepatide is a prescription medicine. Decisions about treatment and monitoring belong with a clinician who knows your health history.

The best tirzepatide data measure whole body composition

The clearest direct evidence comes from a 160 person DXA substudy within the tirzepatide SURMOUNT programme, a larger trial in adults with obesity or overweight. DXA estimates fat mass and nonfat soft tissue, alongside bone mineral. At week 72, the pooled tirzepatide group had lost 21.3% of body weight, 33.9% of fat mass, and 10.9% of lean mass. The study reported that the proportions of fat and lean mass lost were broadly similar across the subgroup analyses it examined.^[1]

That result does not mean 25% of lost body weight was necessarily contractile muscle. Lean mass and fat free mass are broad body composition categories. They include water and tissues beyond skeletal muscle, while a regional scan is not the same thing as a measure of strength or performance. A review in the Journal of the Endocrine Society cautions against treating those labels as interchangeable when interpreting GLP 1 related treatment.^[2]

It also does not answer a glute specific question. The SURMOUNT 1 substudy reports whole body changes, not whether participants kept or built glute muscle or lower body strength. Clothing fit can change for different reasons. This is a group average. The tirzepatide evidence base does not turn a body shape concern into a diagnosis. A clinician or qualified exercise professional can help decide whether a regional assessment, strength measure, or a different monitoring plan is useful.^[2]

Lean mass loss is not unique to tirzepatide

Weight loss itself commonly includes some lean mass loss. In a 2026 meta analysis of 20 randomized trials, lean mass accounted for an estimated 25.4% of total weight lost with tirzepatide, compared with 26.2% for lifestyle interventions. These pooled estimates describe groups, not a target for an individual. They do show why a lower number on the scale is incomplete information about body composition.^[3]

The same meta analysis found a more favourable average lean mass profile in lifestyle programmes that included resistance training. This is relevant, but it is not proof that a particular lifting programme will preserve one muscle group during tirzepatide treatment. The research base still has limits: trials use different body composition methods, participants, calorie plans, and exercise programmes.^[3]

What resistance training and protein can, and cannot, promise

Resistance training provides a reason for muscle to be used while energy intake is lower. Protein supports dietary adequacy, but neither is a guarantee against every change in lean mass or shape. The review of GLP 1 body composition research identifies resistance training and increased protein intake as possible countermeasures, while also explaining that evidence on tirzepatide and body composition needs careful interpretation.^[2]

Relevant clinical questions include food tolerance and safe exercise, plus meaningful changes in strength or daily function. Reduced appetite, an injury, or medicines that affect blood glucose can change what is appropriate. The tirzepatide safety information also matters. Those questions need an individual clinical conversation rather than a copied routine.^[4]

Measure the concern, not only body weight

For someone whose goal includes keeping lower body strength or muscle, body weight alone cannot show whether that goal is being met. Repeated performance measures, training records, symptoms, dietary tolerance, and when clinically appropriate, body composition testing can give a more useful picture. The right measurement depends on the person and the setting. Compare those results with the wider tirzepatide research, rather than treating a consumer body composition device as interchangeable with DXA or an assessment of function.^[2]

Readers can also use the tirzepatide evidence page for the wider trial and safety context, and its regulation section for medicine status. The important limitation remains simple: current studies can describe average changes in fat and lean mass, but they cannot promise preservation of a specific body area for an individual.^[1][3]

What we do not yet know

There is no completed trial that establishes a specific resistance training and protein approach as a proven way to preserve glute muscle during tirzepatide treatment. A registered randomized trial is testing resistance exercise, protein, and their combination alongside semaglutide or tirzepatide, with MRI measured quadriceps area and functional outcomes. Its protocol shows that this question is being studied, not that the strategy has already been proven. Evidence on targeted lower body preservation remains absent.^[5]